QRS duration, bundle-branch block morphology, and outcomes among older patients with heart failure receiving cardiac resynchronization therapy
- PMID: 23942680
- DOI: 10.1001/jama.2013.8641
QRS duration, bundle-branch block morphology, and outcomes among older patients with heart failure receiving cardiac resynchronization therapy
Abstract
Importance: The benefits of cardiac resynchronization therapy (CRT) in clinical trials were greater among patients with left bundle-branch block (LBBB) or longer QRS duration.
Objective: To measure associations between QRS duration and morphology and outcomes among patients receiving a CRT defibrillator (CRT-D) in clinical practice.
Design, setting, and participants: Retrospective cohort study of Medicare beneficiaries in the National Cardiovascular Data Registry's ICD Registry between 2006 and 2009 who underwent CRT-D implantation. Patients were stratified according to whether they were admitted for CRT-D implantation or for another reason, then categorized as having either LBBB or no LBBB and QRS duration of either 150 ms or greater or 120 to 149 ms.
Main outcomes and measures: All-cause mortality; all-cause, cardiovascular, and heart failure readmission; and complications. Patients underwent follow-up for up to 3 years, with follow-up through December 2011.
Results: Among 24 169 patients admitted for CRT-D implantation, 1-year and 3-year mortality rates were 9.2% and 25.9%, respectively. All-cause readmission rates were 10.2% at 30 days and 43.3% at 1 year. Both the unadjusted rate and adjusted risk of 3-year mortality were lowest among patients with LBBB and QRS duration of 150 ms or greater (20.9%), compared with LBBB and QRS duration of 120 to 149 ms (26.5%; adjusted hazard ratio [HR], 1.30 [99% CI, 1.18-1.42]), no LBBB and QRS duration of 150 ms or greater (30.7%; HR, 1.34 [99% CI, 1.20-1.49]), and no LBBB and QRS duration of 120 to 149 ms (32.3%; HR, 1.52 [99% CI, 1.38-1.67]). The unadjusted rate and adjusted risk of 1-year all-cause readmission were also lowest among patients with LBBB and QRS duration of 150 ms or greater (38.6%), compared with LBBB and QRS duration of 120 to 149 ms (44.8%; adjusted HR, 1.18 [99% CI, 1.10-1.26]), no LBBB and QRS duration of 150 ms or greater (45.7%; HR, 1.16 [99% CI, 1.08-1.26]), and no LBBB and QRS duration of 120 to 149 ms (49.6%; HR, 1.31 [99% CI, 1.23-1.40]). There were no observed associations with complications.
Conclusions and relevance: Among fee-for-service Medicare beneficiaries undergoing CRT-D implantation in clinical practice, LBBB and QRS duration of 150 ms or greater, compared with LBBB and QRS duration less than 150 ms or no LBBB regardless of QRS duration, was associated with lower risk of all-cause mortality and of all-cause, cardiovascular, and heart failure readmissions.
Similar articles
-
Sex-specific mortality risk by QRS morphology and duration in patients receiving CRT: results from the NCDR.J Am Coll Cardiol. 2014 Sep 2;64(9):887-94. doi: 10.1016/j.jacc.2014.06.1162. J Am Coll Cardiol. 2014. PMID: 25169173
-
Comparative effectiveness of cardiac resynchronization therapy with an implantable cardioverter-defibrillator versus defibrillator therapy alone: a cohort study.Ann Intern Med. 2014 May 6;160(9):603-11. doi: 10.7326/M13-1879. Ann Intern Med. 2014. PMID: 24798523
-
Cardiac resynchronization therapy in women versus men: observational comparative effectiveness study from the National Cardiovascular Data Registry.Circ Cardiovasc Qual Outcomes. 2015 Mar;8(2 Suppl 1):S4-11. doi: 10.1161/CIRCOUTCOMES.114.001548. Epub 2015 Feb 24. Circ Cardiovasc Qual Outcomes. 2015. PMID: 25714821
-
Defining left bundle branch block in the era of cardiac resynchronization therapy.Am J Cardiol. 2011 Mar 15;107(6):927-34. doi: 10.1016/j.amjcard.2010.11.010. Am J Cardiol. 2011. PMID: 21376930 Review.
-
Opportunity to increase life span in narrow QRS cardiac resynchronization therapy recipients by deactivating ventricular pacing: evidence from randomized controlled trials.JACC Heart Fail. 2015 Apr;3(4):327-36. doi: 10.1016/j.jchf.2014.11.007. Epub 2015 Mar 11. JACC Heart Fail. 2015. PMID: 25770400 Review.
Cited by
-
Potential Underestimation of Left Ventricular Mechanical Dyssynchrony in Dyssynchrony and Outcomes Assessment.J Multidiscip Healthc. 2024 Apr 20;17:1721-1729. doi: 10.2147/JMDH.S450264. eCollection 2024. J Multidiscip Healthc. 2024. PMID: 38659634 Free PMC article.
-
QRS micro-fragmentation as a mortality predictor.Eur Heart J. 2022 Oct 21;43(40):4177-4191. doi: 10.1093/eurheartj/ehac085. Eur Heart J. 2022. PMID: 35187560 Free PMC article.
-
Use and Outcomes of Dual Chamber or Cardiac Resynchronization Therapy Defibrillators Among Older Patients Requiring Ventricular Pacing in the National Cardiovascular Data Registry Implantable Cardioverter Defibrillator Registry.JAMA Netw Open. 2021 Jan 4;4(1):e2035470. doi: 10.1001/jamanetworkopen.2020.35470. JAMA Netw Open. 2021. PMID: 33496796 Free PMC article.
-
Defining Left Bundle Branch Block Patterns in Cardiac Resynchronisation Therapy: A Return to His Bundle Recordings.Arrhythm Electrophysiol Rev. 2020 Jun 3;9(1):28-33. doi: 10.15420/aer.2019.12. Arrhythm Electrophysiol Rev. 2020. PMID: 32637117 Free PMC article. Review.
-
Validation of Three European Risk Scores to Predict Long-Term Outcomes for Patients Receiving Cardiac Resynchronization Therapy in an Asian Population.J Cardiovasc Transl Res. 2021 Aug;14(4):754-760. doi: 10.1007/s12265-020-09999-y. Epub 2020 May 5. J Cardiovasc Transl Res. 2021. PMID: 32372168
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
